Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Combination With AB248 in Extensive Stage Small Cell Lung Cancer
NCT07037758Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Sep 2025
- Primary completion
- Mar 2028
- Modality
- Bispecific Antibodies, T-cell Engagers, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label trial of etakafusp alfa in small cell lung cancer (SCLC) (2 arms), sponsored by Amgen. Primary endpoints: Number of Participants with Treatment-emergent Adverse Events up to 2.5 years and Number of Participants with Dose-limiting Toxicities up to 35 days. Started Sep 2025; status: recruiting.
02
Drugs
etakafusp alfa
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07037758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037758.